Mixture 4F Stem Cell Composition for Angiogenic Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ischemic vascular diseases, such as heart disease and stroke, face challenges in effectively regenerating ischemic tissue due to limited angiogenesis and the senescence of patient-derived stem cells, leading to unsatisfactory outcomes and safety issues with existing angiogenesis promoters.
Innovation Solution
A composition containing fucoidan, tauroursodeoxycholic acid, and vascular endothelial growth factor is developed to inhibit senescence, promote proliferation, and induce differentiation of stem cells, enhancing their angiogenic potential and regenerative capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adult stem cells are used for clinical application in angiogenesis therapy, then ethical issues are avoided and auto-transplantation is possible, but the cells undergo senescence and functional deterioration leading to limited regenerative capability
Solution Approach 1:
The patent applies parameter changes by modifying the culture conditions and composition parameters of stem cell culture media. Specifically, it optimizes concentrations of growth factors (such as VEGF, FGF), cytokines, and culture medium components to maintain stem cell functionality and prevent senescence during in vitro expansion, thereby resolving the contradiction between safety and regenerative capability
Solution Approach 2:
The patent implements preliminary action by pre-treating and optimizing stem cells through controlled in vitro expansion and differentiation protocols before transplantation. This includes pre-differentiating stem cells into vascular progenitor cells under optimized culture conditions to enhance their angiogenic potential prior to clinical application, thus improving regenerative capability while maintaining safety
2Productivity
If angiogenesis promoters are administered directly to promote vascular endothelial cell proliferation, then blood vessel formation is stimulated, but side effects and safety issues occur reducing treatment effectiveness
Solution Approach 1:
The patent uses stem cells and vascular progenitor cells as intermediary carriers to deliver angiogenic functions. Instead of administering angiogenesis promoters directly, the patent employs biologically active cells that naturally secrete growth factors and cytokines (such as VEGF, b-FGF, HGF) to promote angiogenesis in a controlled and safe manner, thereby resolving the contradiction between angiogenesis effect and safety
Solution Approach 2:
The patent implements self-service by enabling transplanted stem cells to autonomously secrete necessary growth factors and cytokines at the target site. The cells self-regulate the angiogenesis process by producing their own paracrine factors (VEGF, FGF, HGF, IL-8) in response to ischemic conditions, eliminating the need for external angiogenesis promoters and their associated side effects
Data Source
AI summary
The present disclosure relates to a composition for increasing the biological activity of stem cells using mixture 4F. Stem cells treated with mixture 4F according to the present disclosure not only acquire undifferentiated characteristics (stemness), but also have the advantage of improving cell proliferative ability and mobility, and thus, after being transplanted into a body, the stem cells can improve cell survival and engraftment and further enhance the ability to regenerate blood vessels and tissues. Accordingly, the stem cells can have various applications in the fields of stem cell differentiation and ischemic disease prevention or treatment.